6 years of historical data (2019–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Roivant Sciences Ltd. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Market Cap | $1.1B | $7.3B | $8.8B | $5.3B | $3.3B | $6.7B | — |
| Enterprise Value | $-1490995450 | $4.7B | $2.7B | $4.1B | $1.5B | $4.8B | — |
| P/E Ratio → | -120.58 | — | 2.02 | — | — | — | — |
| P/S Ratio | 38.70 | 251.93 | 267.76 | 85.84 | 59.84 | 281.46 | — |
| P/B Ratio | 4.05 | 1.41 | 1.36 | 3.27 | 1.60 | 3.10 | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 161.91 | 83.25 | 66.33 | 27.71 | 202.12 | — |
| EV / EBITDA | — | — | 0.60 | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Roivant Sciences Ltd. earns an operating margin of -3453.3%. Operating margins have compressed from -1917.9% to -3453.3% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -3.0% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 96.9% | 96.9% | 95.1% | 78.6% | 83.8% | 91.4% | 98.3% |
| Operating Margin | -3453.3% | -3453.3% | 13746.9% | -1917.9% | -2444.8% | -4500.5% | -786.6% |
| Net Profit Margin | -592.0% | -592.0% | 13294.2% | -1646.6% | -1528.9% | -3400.9% | 1773.6% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| ROE | -3.0% | -3.0% | 108.0% | -55.0% | -40.0% | -37.9% | 56.9% |
| ROA | -2.7% | -2.7% | 90.5% | -40.6% | -32.0% | -31.3% | 48.5% |
| ROIC | -50.4% | -50.4% | 817.9% | -252.9% | -362.6% | -424.6% | -383.6% |
| ROCE | -16.4% | -16.4% | 99.1% | -52.0% | -55.5% | -44.1% | -22.3% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $2.7B exceeds total debt of $100M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.08 | 0.30 | 0.14 | 0.11 | 0.09 |
| Debt / EBITDA | — | — | 0.11 | — | — | — | — |
| Net Debt / Equity | — | -0.50 | -0.94 | -0.74 | -0.86 | -0.87 | -0.95 |
| Net Debt / EBITDA | — | — | -1.34 | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | — | — | 129.31 | -42.02 | -191.97 | -381.24 | -69.30 |
Net cash position: cash ($2.7B) exceeds total debt ($100M)
Short-term solvency ratios and asset-utilisation metrics
Roivant Sciences Ltd.'s current ratio of 33.47x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 6.60x to 33.47x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 33.47 | 33.47 | 25.24 | 6.60 | 11.64 | 9.99 | 24.09 |
| Quick Ratio | 33.47 | 33.47 | 25.10 | 6.59 | 11.64 | 9.99 | 24.09 |
| Cash Ratio | 32.71 | 32.71 | 24.52 | 6.17 | 11.18 | 9.74 | 23.72 |
| Asset Turnover | — | 0.01 | 0.00 | 0.03 | 0.02 | 0.01 | 0.03 |
| Inventory Turnover | 0.05 | — | 0.05 | 4.75 | — | — | — |
| Days Sales Outstanding | — | — | 924.00 | 224.22 | 44.44 | 212.17 | 82.39 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Roivant Sciences Ltd. returns 100.0% to shareholders annually primarily through share buybacks.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | 0.1% | — | — | — | — |
| Payout Ratio | — | — | 0.1% | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 49.6% | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 100.0% | 17.7% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 100.0% | 17.7% | 0.1% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $725M | $831M | $713M | $670M | $685M | $685M |
Compare ROIV with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| ROIVYou | $1B | -120.6 | — | — | 96.9% | -3453.3% | -3.0% | -50.4% | — |
| REGN | $108B | 18.8 | 21.6 | 26.4 | 86.3% | 25.7% | 14.9% | 12.4% | 0.6 |
| CNTA | $4B | -13.0 | — | — | — | — | -73.9% | -91.8% | — |
| IMNM | $2B | -4.4 | — | — | 100.0% | -3382.4% | -194.6% | -700.3% | — |
| CLDX | $2B | -7.7 | — | — | 100.0% | -19160.0% | -40.6% | -35.2% | — |
| RXRX | $2B | -2.5 | — | — | 5.0% | -867.9% | -59.5% | -95.8% | — |
| NRIX | $2B | -5.2 | — | — | 77.5% | -340.2% | -49.6% | -54.0% | — |
| ABCL | $1B | -7.4 | — | — | — | -289.0% | -14.5% | -16.8% | — |
| ARVN | $975M | -10.4 | — | — | -151.8% | -45.1% | -16.2% | -23.1% | — |
| XNCR | $918M | -10.3 | — | — | — | — | -9.5% | — | — |
| TECX | $439M | -6.0 | — | — | — | — | -206.6% | — | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 6 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how ROIV stacks up against sector leader Regeneron Pharmaceuticals, Inc..
Start ComparisonRoivant Sciences Ltd.'s current P/E ratio is -120.6x. The historical average is 2.0x.
Roivant Sciences Ltd.'s return on equity (ROE) is -3.0%. The historical average is 4.8%.
Based on historical data, Roivant Sciences Ltd. is trading at a P/E of -120.6x. Compare with industry peers and growth rates for a complete picture.
Roivant Sciences Ltd. has 96.9% gross margin and -3453.3% operating margin.